Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19090894 | EMAIL SUBJECT LINE GENERATION METHOD | March 2025 | February 2026 | Allow | 11 | 1 | 0 | No | No |
| 18922120 | INTELLIGENT DETECTION AND ACQUISITION OF AUTHENTIC PRODUCT REVIEWS FOR CROSS-PLATFORM AVAILABILITY | October 2024 | October 2025 | Allow | 12 | 0 | 0 | No | No |
| 18783055 | CONSUMER SENTIMENT ANALYSIS FOR SELECTION OF CREATIVE ELEMENTS | July 2024 | January 2026 | Allow | 17 | 1 | 0 | No | No |
| 18777458 | SYSTEMS AND METHODS FOR IMPLEMENTING A REACTIVE AND TRANSACTIVE ECOSYSTEM | July 2024 | February 2026 | Abandon | 19 | 1 | 0 | No | No |
| 18752098 | MEDICAL FLUID DELIVERY SYSTEM INCLUDING A MOBILE PLATFORM FOR PATIENT ENGAGEMENT AND TREATMENT COMPLIANCE | June 2024 | July 2025 | Allow | 13 | 0 | 0 | No | No |
| 18739383 | FEW-SHOT ELECTROCARDIOGRAM (ECG) SIGNAL CLASSIFICATION METHOD BASED ON IMPROVED SIAMESE NETWORK | June 2024 | July 2025 | Allow | 13 | 0 | 0 | No | No |
| 18702446 | DUAL-MODE MOBILE WI-FI OTOSCOPE SYSTEM AND METHODS | April 2024 | February 2026 | Allow | 22 | 1 | 0 | No | No |
| 18634319 | MANAGEMENT OF MEDICAL EQUIPMENT AND RESPONDERS | April 2024 | July 2025 | Allow | 15 | 1 | 0 | Yes | No |
| 18625664 | COLLECTING AND CONNECTING VASCULAR ACCESS DATA THROUGHOUT THE CONTINUITY OF CARE | April 2024 | January 2026 | Allow | 21 | 1 | 0 | Yes | No |
| 18425509 | METHODS AND SYSTEMS FOR PREDICTING DELAYS IN EMERGENCY DEPARTMENT WORKFLOW | January 2024 | December 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18569843 | EMERGENCY TREATMENT SYSTEM FOR INJURED OR SICK PERSONS | December 2023 | November 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18493978 | METHOD FOR IDENTIFYING AND TREATING HEART FAILURE WITH PRESERVED EJECTION FRACTION | October 2023 | October 2025 | Allow | 24 | 1 | 0 | No | No |
| 18378325 | METHODS AND SYSTEMS FOR OPTIMIZED CUSTOMER RELATIONSHIP MANAGEMENT IN HEALTHCARE | October 2023 | November 2025 | Abandon | 26 | 1 | 0 | No | No |
| 18228932 | GENERATING A MEDICAL KNOWLEDGE PACKET IN AN ACTIVE CONVERSATION SESSION | August 2023 | December 2024 | Allow | 16 | 2 | 0 | Yes | No |
| 18267148 | RISK DISPLAY APPARATUS, RISK DISPLAY METHOD, AND NON-TRANSITORY COMPUTER READABLE MEDIUM | June 2023 | September 2025 | Allow | 27 | 1 | 0 | Yes | No |
| 18266899 | AUTOMATIC RANKING AND RANK ORDER DISPLY OF MEDICAL INFORMATION, AND ASSOCIATED DEVICES, SYSTEMS, AND METHODS | June 2023 | September 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18251688 | EFFICIENT STORAGE OF DRUG LIBRARY EDITOR ENTRIES | May 2023 | April 2025 | Allow | 24 | 1 | 0 | Yes | No |
| 18142157 | APPLICATION FOR TRACKING PROGRESSION AND ISOLATING CAUSES OF ADVERSE MEDICAL CONDITIONS | May 2023 | June 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18137309 | IDENTIFYING VALUE CONSCIOUS USERS | April 2023 | May 2025 | Abandon | 25 | 4 | 0 | Yes | No |
| 18032443 | Digital Platform for Infectious Disease Tracking and Testing Support | April 2023 | June 2025 | Allow | 26 | 1 | 0 | No | No |
| 18181479 | MACHINE LEARNING-BASED EXERCISE RECOMMENDATION ADJUSTMENT BASED ON USER FEEDBACK | March 2023 | October 2025 | Allow | 31 | 2 | 0 | No | No |
| 18021722 | INFORMATION PROCESSING DEVICE AND INFORMATION PROCESSING METHOD | February 2023 | April 2025 | Allow | 26 | 1 | 0 | Yes | No |
| 17957694 | AUTONOMOUS MEDICAL SCREENING AND RECOGNITION ROBOTS, SYSTEMS AND METHOD OF IDENTIFYING A DISEASE, CONDITION, OR INJURY | September 2022 | June 2025 | Allow | 32 | 1 | 0 | Yes | No |
| 17940628 | AUGMENTING FILES SUCH AS DICOM OBJECTS CONTAINING MEDICAL IMAGING INFORMATION WITH ADDITIONAL MEDICAL INFORMATION ABOUT THE SUBJECT OF THE MEDICAL IMAGING INFORMATION | September 2022 | October 2024 | Allow | 25 | 1 | 0 | No | No |
| 17894764 | AUTONOMOUS MEDICAL RESCUE ROBOTS AND TEAMS | August 2022 | August 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17801241 | PERSONAL COMPOSITE INFORMATION-BASED HEALTHCARE SOLUTION PROVISION METHOD AND SYSTEM | August 2022 | May 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17818257 | COORDINATED PROCESSING AND SCHEDULING FOR SURGICAL PROCEDURES | August 2022 | August 2025 | Allow | 36 | 2 | 0 | No | No |
| 17816416 | Home Health Optimization via Connected Providers | July 2022 | October 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17855625 | Email Subject Line Generation Method | June 2022 | December 2024 | Allow | 29 | 2 | 0 | No | No |
| 17836264 | PROVIDING HEALTHCARE VIA AUTONOMOUS, SELF-LEARNING, AND SELF-EVOLUTIONARY PROCESSES | June 2022 | December 2024 | Allow | 30 | 1 | 0 | Yes | No |
| 17780738 | PREDICTION DEVICE | May 2022 | September 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17777984 | MEDICAL TREATMENT PLANNING SYSTEM AND METHOD WITH MACHINE LEARNING | May 2022 | January 2026 | Allow | 44 | 3 | 0 | Yes | No |
| 17777477 | AUTOMATED PROTOCOLING IN MEDICAL IMAGING SYSTEMS | May 2022 | February 2025 | Allow | 33 | 2 | 0 | Yes | No |
| 17777520 | BEACON-BASED SYSTEMS AND METHODS FOR COMMUNICATIVELY PAIRING A DEVICE WITH A MEDICAL SYSTEM | May 2022 | February 2025 | Allow | 33 | 1 | 0 | Yes | No |
| 17777448 | A METHOD AND SYSTEM FOR GENERATING AN INPUT FOR A SEARCH ENGINE | May 2022 | October 2024 | Allow | 29 | 1 | 0 | No | No |
| 17777253 | METHOD AND DEVICE FOR PREDICTING USER STATE | May 2022 | August 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17742918 | HEALTH MANAGEMENT SYSTEM | May 2022 | September 2025 | Abandon | 40 | 1 | 1 | No | No |
| 17740885 | Autonomous Self-Driving Vehicle with Advertising Platform | May 2022 | January 2025 | Allow | 32 | 2 | 0 | No | No |
| 17737223 | ELECTRONIC MEDICAL RECORDS AND TEMPLATE SYSTEM | May 2022 | October 2024 | Abandon | 30 | 1 | 0 | No | No |
| 17691751 | Systems and Methods For Electronically Monitoring Expected Adverse Reactions Of Pharmaceutical Products | March 2022 | February 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17641190 | A Monitoring System and Method | March 2022 | March 2025 | Allow | 36 | 2 | 0 | Yes | No |
| 17688542 | GENERATIVE MOTION MODELING USING EXTERNAL AND INTERNAL ANATOMY INFORMATION | March 2022 | October 2025 | Abandon | 43 | 4 | 0 | Yes | No |
| 17587969 | SENIOR LIVING ENGAGEMENT AND CARE SUPPORT PLATFORMS WITH CHATBOT AND LIST INTEGRATION | January 2022 | October 2024 | Allow | 32 | 2 | 0 | No | No |
| 17581563 | POINT-OF-CARE CLINICAL DECISION SUPPORT PLATFORM | January 2022 | July 2024 | Allow | 30 | 1 | 0 | No | No |
| 17455790 | COMPUTERIZED SYSTEMS AND METHODS FOR LIVESTOCK MANAGEMENT | November 2021 | February 2025 | Allow | 39 | 3 | 0 | No | No |
| 17496313 | SYSTEMS AND METHODS FOR ANALYZING, MANAGING AND IMPROVING SLEEP | October 2021 | July 2025 | Allow | 45 | 2 | 0 | No | No |
| 17388661 | METHOD AND SYSTEM FOR EMPOWERING CANCER PATIENT(S) | July 2021 | May 2025 | Abandon | 45 | 4 | 0 | No | No |
| 17170647 | RECOMMENDATION SYSTEM WITH ADAPTIVE THRESHOLDS FOR NEIGHBORHOOD SELECTION | February 2021 | April 2025 | Abandon | 50 | 4 | 0 | No | No |
| 17136466 | MACHINE LEARNING SYSTEMS FOR AUTOMATED DATABASE ELEMENT PROCESSING AND PREDICTION OUTPUT GENERATION | December 2020 | June 2024 | Allow | 42 | 1 | 1 | No | No |
| 17106588 | METHODS AND SYSTEMS FOR DETERMINING A PREDICTIVE INTERVENTION USING BIOMARKERS | November 2020 | January 2026 | Allow | 60 | 6 | 0 | Yes | No |
| 16735542 | SYSTEMS AND METHODS FOR ADMINISTRATION OF FINANCIAL PRODUCTS | January 2020 | June 2025 | Allow | 60 | 7 | 0 | Yes | No |
| 16265944 | COMPUTER-PROJECTED CONFIDENCE INDICIA | February 2019 | March 2026 | Abandon | 60 | 8 | 0 | Yes | No |
| 16067368 | Geographically Targeted Message Delivery Using Point-of-Sale Data | June 2018 | June 2024 | Allow | 60 | 7 | 1 | No | Yes |
| 15891363 | System and Methods for Operating an Information Exchange | February 2018 | April 2025 | Abandon | 60 | 2 | 1 | Yes | Yes |
| 13658326 | SYSTEM AND METHOD FOR DELIVERY OF MARKETING FOR MULITPLE ENTITIES | October 2012 | November 2024 | Abandon | 60 | 9 | 0 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner TOKARCZYK, CHRISTOPHER B.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner TOKARCZYK, CHRISTOPHER B works in Art Unit 3687 and has examined 11 patent applications in our dataset. With an allowance rate of 54.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 10000 months.
Examiner TOKARCZYK, CHRISTOPHER B's allowance rate of 54.5% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by TOKARCZYK, CHRISTOPHER B receive 4.82 office actions before reaching final disposition. This places the examiner in the 99% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by TOKARCZYK, CHRISTOPHER B is 10000 months. This places the examiner in the 1% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a -26.7% benefit to allowance rate for applications examined by TOKARCZYK, CHRISTOPHER B. This interview benefit is in the 1% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 10.8% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 0.0% of cases where such amendments are filed. This entry rate is in the 3% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 20% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 33.3% of appeals filed. This is in the 5% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 7% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 40% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 43% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.